Table of Content

Executive Summary
1 Market Overview
1.1 Historical Trends
1.2 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
1.3 Clinical Applications of Liquid Biopsy
1.4 Trends for Liquid Biopsy
1.5 Latin America Liquid Biopsy Market Scenario

2 Market Dynamics
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Potential of Liquid Biopsy
2.2.2 Ability to Monitor Clonal Mutations
2.2.3 Growing Prominence of Precision Medicine
2.3 Market Restraints
2.3.1 Uncertain Reimbursement and Regulatory Policies
2.3.2 High Pricing Pressure
2.3.3 Adoption of Traditional Diagnosis Practices
2.4 Market Opportunities
2.4.1 Development of Medication Package Deals
2.4.2 Expansion into Emerging markets
2.4.3 Scope of Liquid Biopsy for Intervention: Diagnosis of Non-Oncology Disorders

3 Competitive Insights
3.1 Market Share Analysis
3.2 Industry Attractiveness
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyer
3.2.3 Threat of New Entrants
3.2.4 Threat of Substitute Products
3.2.5 Intensity of Competitive Rivalry

4 Latin America Liquid Biopsy Market (by Product Type)
4.1 Tests/Services
4.2 Kits and Consumables
4.3 Instruments

5 Latin America Liquid Biopsy Market (by Circulating Biomarkers)
5.1 Circulating Tumor DNA (ctDNA)
5.2 Circulating Tumor Cells (CTCs)
5.3 Cell-Free DNA (cfDNA)
5.4 Extracellular Vesicles and Others

6 Latin America Liquid Biopsy Market (by Clinical Applications)
6.1 Treatment Monitoring
6.2 Prognosis and Recurrence Monitoring
6.3 Treatment Selection
6.4 Diagnosis and Screening

7 Latin America Liquid Biopsy Market (by Therapeutic Applications)
7.1 Breast Cancer
7.2 Lung Cancer
7.3 Prostate Cancer
7.4 Colorectal Cancer
7.5 Melanoma Cancer
7.6 Other Types of Cancer
7.7 Non-Oncology Application

8 Latin America Liquid Biopsy Market (by Country)
8.1 Brazil
8.2 Mexico
8.3 Argentina
8.4 Chile
8.5 Colombia
8.6 Rest-of-Latin America

9 Company Profiles
9.1 Overview
9.2 Biocept, Inc.
9.2.1 Company Overview
9.2.2 Role of Biocept, Inc. in LATAM Liquid Biopsy Market
9.2.3 Overall Financials
9.2.4 Key Insights about Financial Health of the Company
9.2.5 SWOT Analysis
9.3 Bio-Rad Laboratories, Inc.
9.3.1 Company Overview
9.3.2 Role of Bio-Rad Laboratories, Inc. in LATAM Liquid Biopsy Market
9.3.3 Overall Financials
9.3.4 Key Insights about Financial Health of the Company
9.3.5 SWOT Analysis
9.4 Contextual Genomics Inc.
9.4.1 Company Overview
9.4.2 Role of Contextual Genomics Inc. in LATAM Liquid Biopsy Market
9.4.3 SWOT Analysis
9.5 Epic Sciences, Inc.
9.5.1 Company Overview
9.5.2 Role of Epic Sciences, Inc. in the LATAM Liquid Biopsy Market
9.5.3 SWOT Analysis
9.6 F. Hoffmann-La Roche AG
9.6.1 Company Overview
9.6.2 Role of F. Hoffmann-La Roche AG in the LATAM Liquid Biopsy Market
9.6.3 Overall Financials
9.6.4 Key Insights about Financial Health of the Company
9.6.5 SWOT Analysis
9.7 Guardant Health, Inc.
9.7.1 Company Overview
9.7.2 Role of Guardant Health, Inc. in LATAM Liquid Biopsy Market
9.7.3 SWOT Analysis
9.8 Illumina, Inc.
9.8.1 Company Overview
9.8.2 Role of Illumina, Inc. in the LATAM Liquid Biopsy Market
9.8.3 Overall Financials
9.8.4 Key Insights about Financial Health of the Company
9.8.5 SWOT Analysis
9.9 MDxHealth Inc.
9.9.1 Company Overview
9.9.2 Role of MDxHealth, Inc. in the LATAM Liquid Biopsy Market
9.9.3 Overall Financials
9.9.4 Key Insights on the Financial Health of the Company
9.9.5 SWOT Analysis
9.10 Menarini Silicon Biosystems (Subsidiary of Menarini Group)
9.10.1 Company Overview
9.10.2 Role of Menarini Silicon Biosystems in the LATAM Liquid Biopsy Market
9.10.3 SWOT Analysis
9.11 MetaCell s.r.o
9.11.1 Company Overview
9.11.2 Role of MetaCell s.r.o in LATAM Liquid Biopsy Market
9.11.3 SWOT Analysis
9.12 Myriad Genetics, Inc.
9.12.1 Company Overview
9.12.2 Role of Myriad Genetics, Inc. in LATAM Liquid Biopsy Market
9.12.3 Overall Financials
9.12.4 Key Insights of the Financial Health of the Company
9.12.5 SWOT Analysis
9.13 NeoGenomics Laboratories, Inc.
9.13.1 Company Overview
9.13.2 Role of NeoGenomics Laboratories, Inc. in the LATAM Liquid Biopsy Market
9.13.3 Overall Financials
9.13.4 Key Insights on the Financial Health of the Company
9.13.5 SWOT Analysis
9.14 Qiagen N.V.
9.14.1 Company Overview
9.14.2 Role of Qiagen N.V. in the Liquid Biopsy Market
9.14.3 Overall Financials
9.14.4 Key Insights on the Financial Health of the Company
9.14.5 SWOT Analysis
9.15 Sysmex Inostics GmbH (Subsidiary of Sysmex Corporation)
9.15.1 Company Overview
9.15.2 Role of Sysmex Inostics GmbH in LATAM Liquid Biopsy Market
9.15.3 SWOT Analysis
9.16 Thermo Fisher Scientific Inc.
9.16.1 Company Overview
9.16.2 Role of Thermo Fisher Scientific Inc. in LATAM Liquid Biopsy Market
9.16.3 Financials
9.16.4 Key Insights on the Financial Health of the Company
9.16.5 SWOT Analysis

10 Research Scope and Methodology
10.1 Report Scope



List of Tables

Table: 1.1 Tissue Biopsy vs. Liquid Biopsy
Table: 2.1 Impact Analysis
Table: 2.2 Governmental Initiatives for the Market Growth of Precision Medicine
Table: 2.3 Incidence of Leading Cancer Types (by Country), 2018 and 2040
Table: 7.1 Breast Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.2 Lung Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.3 Prostate Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.4 Colorectal Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.5 Melanoma Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.6 Ovarian Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 7.7 Stomach Cancer Incidence in Latin American Countries, 2018, 2020, 2025, and 2030
Table: 8.1 Healthcare Expenditure (US$ per head) in Latin American Countries, 2015-2017
Table: 8.2 Brazil: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.3 Mexico: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.4 Argentina: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.5 Chile: Prevalence of Different Types of Cancer, 2018-2030
Table: 8.6 Colombia: Prevalence of Different Types of Cancer, 2018-2030

List of Figures



Figure: 1 Few Citations of Liquid Biopsy
Figure: 2 Latin America Market Drivers and Restraints
Figure: 3 Latin America Liquid Biopsy Market, 2017-2025
Figure: 4 Latin America Liquid Biopsy Market (by Product Type), 2017 and 2025
Figure: 5 Latin America Liquid Biopsy Market (by Circulating Biomarkers), 2017 and 2025
Figure: 6 Latin America Liquid Biopsy Market (by Clinical Application), 2017-2025
Figure: 7 Latin America Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8 Latin America Liquid Biopsy Market (by Country), 2017-2025
Figure: 9 Adoption Rate: Tissue Biopsy vs. Liquid biopsy
Figure: 1.1 Different Types of Biomarkers in Liquid Biopsy
Figure: 1.2 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
Figure: 1.3 Workflow Model of Tissue and Liquid Biopsy
Figure: 1.4 Clinical Applications of Liquid Biopsy
Figure: 1.5 Latin America Liquid Biopsy Market, 2017-2025
Figure: 2.1 Market Dynamics of LATAM Liquid Biopsy Market
Figure: 3.1 Market Share Analysis: Latin America Liquid Biopsy Market, 2016 and 2017
Figure: 3.2 Porter’s Five Forces Analysis
Figure: 3.3 Bargaining Power of Suppliers: Overall Impact, 2014-2025
Figure: 3.4 Bargaining Power of Buyers: Overall Impact, 2014-2025
Figure: 3.5 Threat of New Entrant: Overall Impact, 2014-2025
Figure: 3.6 Threat of Substitute Products: Overall Impact, 2014-2025
Figure: 3.7 Intensity of Competitive Rivalry: Overall Impact, 2014-2025
Figure: 4.1 Latin America Liquid Biopsy Market (by Circulating Biomarkers)
Figure: 4.2 Liquid Biopsy Market (by Product Type), 2017-2025
Figure: 4.3 Latin America Liquid Biopsy Market (by Tests/Services), 2017-2025
Figure: 4.4 Latin America Liquid Biopsy Market (by Kits and Consumables), 2017-2025
Figure: 4.5 Latin America Liquid Biopsy Market (by Instruments), 2017-2025
Figure: 5.1 Different Circulating Biomarkers
Figure: 5.2 Latin America Liquid Biopsy Market (by Circulating Biomarkers)
Figure: 5.3 Latin America Liquid Biopsy Market (by Circulating Biomarker), 2017 and 2025
Figure: 5.4 Latin America Liquid Biopsy Market (by ctDNA), 2017-2025
Figure: 5.5 CTCs vs. ctDNA Analysis
Figure: 5.6 Latin America Liquid Biopsy Market (by CTCs), 2017-2025
Figure: 5.7 Latin America Liquid Biopsy Market (by cfDNA), 2017-2025
Figure: 5.8 Latin America Liquid Biopsy Market (by Extracellular Vesicles and Others), 2017-2025
Figure: 6.1 Latin America Liquid Biopsy Market (by Clinical Applications)
Figure: 6.2 Liquid Biopsy Market (by Clinical Application), 2017-2025
Figure: 6.3 Latin America Liquid Biopsy Market (by Treatment Monitoring), 2017-2025
Figure: 6.4 Latin America Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2017-2025
Figure: 6.5 Latin America Liquid Biopsy Market (by Treatment Selection), 2017-2025
Figure: 6.6 Latin America Liquid Biopsy Market (by Diagnosis and Screening), 2017-2025
Figure: 7.1 Latin America Liquid Biopsy Market (by Therapeutic Applications)
Figure: 7.2 Latin America Liquid Biopsy Market (by Therapeutic Applications), 2017-2025
Figure: 7.3 Types of Breast Cancer
Figure: 7.4 Latin America Liquid Biopsy Market (by Breast Cancer), 2017-2025
Figure: 7.5 Types of Lung Cancer
Figure: 7.6 Latin America Liquid Biopsy Market (by Lung Cancer), 2017-2025
Figure: 7.7 Latin America Liquid Biopsy Market (by Prostate Cancer), 2017-2025
Figure: 7.8 Latin America Liquid Biopsy Market (by Colorectal Cancer), 2017-2025
Figure: 7.9 Latin America Liquid Biopsy Market (by Melanoma Cancer), 2017-2025
Figure: 7.10 Latin America Liquid Biopsy Market (by Other Types of Cancer), 2017-2025
Figure: 7.11 Latin America Liquid Biopsy Market (by Non-Oncology), 2017-2025
Figure: 8.1 Latin America Liquid Biopsy Market, 2017-2025
Figure: 8.2 Latin America Liquid Biopsy Market (by Country), 2017-2025
Figure: 8.3 Brazil Liquid Biopsy Market, 2017-2025
Figure: 8.4 Brazil Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.5 Mexico Liquid Biopsy Market, 2017-2025
Figure: 8.6 Mexico: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.7 Argentina Liquid Biopsy Market, 2017-2025
Figure: 8.8 Argentina: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.9 Chile Liquid Biopsy Market, 2017-2025
Figure: 8.10 Chile: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.11 Colombia Liquid Biopsy Market, 2017-2025
Figure: 8.12 Colombia: Liquid Biopsy Market (by Therapeutic Application), 2017-2025
Figure: 8.13 Rest-of-Latin America Liquid Biopsy Market, 2017-2025
Figure: 9.1 Shares of Key Company Profiles
Figure: 9.2 Product Offerings
Figure: 9.3 Biocept, Inc.: Overall Financials, 2015-2017
Figure: 9.4 Biocept, Inc.: R&D Expense, 2015-2017
Figure: 9.5 Biocept, Inc.: SWOT Analysis
Figure: 9.6 Bio-Rad Laboratories, Inc.: Product Offerings
Figure: 9.7 Bio-Rad laboratories, Inc.: Overall Financials, 2015-2017
Figure: 9.8 Bio-Rad Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.9 Bio-Rad Laboratories, Inc.: Revenue (by Region), 2015-2017
Figure: 9.10 Bio-Rad Laboratories, Inc.: R&D Expense, 2015-2017
Figure: 9.11 Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure: 9.12 Contextual Genomics Inc.: SWOT Analysis
Figure: 9.13 Epic Sciences, Inc.: Product Offerings
Figure: 9.14 Epic Sciences, Inc.: SWOT Analysis
Figure: 9.15 F. Hoffmann-La Roche AG: Product Offerings
Figure: 9.16 F. Hoffmann-La Roche AG: Overall Financials, 2015-2017
Figure: 9.17 F. Hoffmann-La Roche AG: Revenue (by Business Segment), 2015-2017
Figure: 9.18 F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics Sub-division), 2015-2017
Figure: 9.19 F. Hoffmann-La Roche AG: Revenue (by Region), 2015-2017
Figure: 9.20 F. Hoffmann-La Roche AG: R&D Expense, 2015-2017
Figure: 9.21 F. Hoffmann-La Roche AG: SWOT Analysis
Figure: 9.22 Guardant Health, Inc.: Product Offerings
Figure: 9.23 Guardant Health, Inc.: SWOT Analysis
Figure: 9.24 Illumina, Inc.: Product Offerings
Figure: 9.25 Illumina, Inc.: Overall Financials, 2015-2017
Figure: 9.26 Illumina, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.27 Illumina, Inc.: Revenue (by Region), 2015-2017
Figure: 9.28 Illumina, Inc.: R&D Expense, 2015-2017
Figure: 9.29 Illumina, Inc.: SWOT Analysis
Figure: 9.30 MDxHealth, Inc.: Product Offerings
Figure: 9.31 MDxHealth, Inc.: Overall Financials, 2015-2017
Figure: 9.32 MDxHealth, Inc.: R&D Expanse, 2015-2017
Figure: 9.33 MDxHealth, Inc.: SWOT Analysis
Figure: 9.34 Menarini Silicon Biosystems, Inc.: Product Offerings
Figure: 9.35 Menarini Silicon Biosystems, Inc.: SWOT Analysis
Figure: 9.36 Metacell s.r.o: SWOT Analysis
Figure: 9.37 Myriad Genetics, Inc.: Product Offerings
Figure: 9.38 Myriad Genetics, Inc.: Overall Financials, 2015-2017
Figure: 9.39 Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.40 Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
Figure: 9.41 Myriad Genetics, Inc.: R&D Expense, 2015-2017
Figure: 9.42 Myriad Genetics, Inc.: SWOT Analysis
Figure: 9.43 NeoGenomics Laboratories, Inc.: Product Offerings
Figure: 9.44 NeoGenomics Laboratories, Inc.: Overall Financials, 2015-2017
Figure: 9.45 NeoGenomics Laboratories, Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.46 NeoGenomics Laboratories, Inc.: R&D Expense, 2015-2017
Figure: 9.47 NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure: 9.48 Qiagen N.V.: Product Offerings
Figure: 9.49 Qiagen N.V.: Overall Financials, 2015-2017
Figure: 9.50 Qiagen N.V.: Revenue (by Business Segment), 2015-2017
Figure: 9.51 Qiagen N.V.: Revenue (by Region), 2015-2017
Figure: 9.52 Qiagen N.V.: R&D Expense, 2015-2017
Figure: 9.53 Qiagen N.V.: SWOT Analysis
Figure: 9.54 Sysmex Inostics GmbH: Product Offerings
Figure: 9.55 Sysmex Inostics GmbH: SWOT Analysis
Figure: 9.56 Thermo Fisher Scientific Inc.: Product Offerings
Figure: 9.57 Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure: 9.58 Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
Figure: 9.59 Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure: 9.60 Thermo Fisher Scientific Inc.: R&D Expense, 2015-2017
Figure: 9.61 Thermo Fisher Scientific Inc.: SWOT Analysis
Figure: 10.1 Latin America Liquid Biopsy: Market Segmentation
Figure: 10.2 Latin America Liquid Biopsy Market Segmentation
Figure: 10.3 Primary Research
Figure: 10.4 Secondary Research
Figure: 10.5 Data Triangulation
Figure: 10.6 Top-down Approach (Segment-wise Analysis)
Figure: 10.7 Bottom-up Approach (Segment-wise Analysis)
Figure: 10.8 Assumptions and Limitations
Figure: 10.9 Considered Factors for Data Prediction and Modelling